Evidence map›Paper›PMID 41402322›Full record

Trial reportNature communications2025

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Soumyajit Roy, Yilun Sun, Maha Hussain, Kim N Chi, Karim Fizazi, Ian D Davis, Susan Halabi, Neeraj Agarwal, Simon Chowdhury, Bertrand Tombal and 22 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Soumyajit RoyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine Cleveland, Cleveland, OH, USA. soumyajitroy8@gmail.com.ORCID http://orcid.org/0000-0001-6617-5522
Yilun SunCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Maha HussainDivision of Hematology Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-0380-9465
Kim N ChiBC Cancer and Vancouver Prostate Centre, Vancouver, BC, Canada.
Karim FizaziDepartment of Cancer Medicine, Institut Gustave Roussy, Centre Oscar Lambret, University of Paris-Saclay, Villejuif, France.
Ian D DavisCancer Services, Eastern Health, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-9066-8244
Susan HalabiDepartemnt of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0003-4135-2777
Neeraj AgarwalDivision of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-1076-0428
Simon ChowdhuryGuy's, King's and St. Thomas' Hospitals and Sarah Cannon Research Institute, London, UK.
Bertrand TombalDepartment of Surgery, Université Catholique de Louvain (UCL), Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Scott C MorganDepartment of Radiation Oncology, Radiology, and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Shawn MaloneDepartment of Radiation Oncology, Radiology, and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Pedro C BarataDepartment of Internal Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Michael OngDepartment of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Christopher J D WallisDivision of Urology, Department of Surgery, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5990-4026
Alejandro BerlinRadiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Umang SwamiDivision of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-3518-0411
Amar U KishanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Angela Y JiaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine Cleveland, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-0812-2614
Nicholas G ZaorskyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine Cleveland, Cleveland, OH, USA.
Jorge A GarciaDepartment of Internal Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Prateek MendirattaDepartment of Internal Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Jason R BrownDepartment of Internal Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Vinod V SubhashAustralian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-6050-9915
Martin R StocklerAustralian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-3793-8724
Hayley ThomasAustralian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia.
Rana R McKayMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0581-7963
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3191-6268
Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, SC, USA.
Fred SaadCentre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.ORCID http://orcid.org/0000-0003-2986-5617
Christopher J SweeneySouth Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.ORCID http://orcid.org/0000-0002-0398-6018
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine Cleveland, Cleveland, OH, USA. Daniel.Spratt@uhhospitals.org.ORCID http://orcid.org/0000-0002-5973-4741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an unmet need for a tool that could predict early favorable prostate-specific antigen (PSA) response in metastatic hormone sensitive prostate cancer (mHSPC) patients receiving androgen receptor pathway inhibitor (ARPI). Here, we train and validate a multivariable logistic regression model to predict early favorable PSA response (≤0.2 ng/mL by 6 months) in these patients. Patients randomly allocated to the ARPI arms of the LATITUDE (abiraterone), TITAN (apalutamide), and ARASENS (darolutamide) trials, are split 60:40 into training (n = 1030) and internal validation (n = 688) cohorts. The locked model is validated in an independent external validation cohort - the enzalutamide arm of the ENZAMET trial (n = 540). The area under curve and Brier score for the locked model in the external validation cohort are 0.82 (95% confidence interval [CI] = 0.78-0.85) and 0.16, respectively. Stratification by predicted probability tertiles show PSA response rates of 92% (95% CI = 88-96), 74% (95% CI = 68-81), and 39% (95% CI = 32-47), respectively. Pending prospective validation, our model predicts early favorable PSA response supporting its potential role in guiding treatment decisions.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAgedAndrogen Receptor AntagonistsBenzamidesHumansMaleMiddle AgedNeoplasm MetastasisNitrilesPhenylthiohydantoinReceptors, AndrogenThiohydantoinsTreatment OutcomeAndrogen Receptor AntagonistsapalutamideBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific AntigenReceptors, AndrogenThiohydantoins

Identifiers

PMID41402322
PMCPMC12819402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.